NEW YORK, March 19 – Toronto-based proteomics company Syn X Pharma said Monday it would build the infrastructure to conduct in-house clinical trials.

The company, which recently hired a proteomics executive from Ciphergen and a business development expert from Eli Lilly, said the move signaled its efforts to begin bringing its products to market.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.